Theriva Biologics (TOVX) Assets Average (2011 - 2026)
Theriva Biologics (TOVX) posted quarterly Assets Average of $38.2 million for Q1 2026, up 13.29% year-over-year from $33.8 million in Q1 2025, and up 10.73% quarter-over-quarter from $34.5 million in Q4 2025.
Theriva Biologics (TOVX) Assets Average (2011 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Assets Average for 16 consecutive years, with $38.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 13.29% year-over-year to $38.2 million; the TTM figure through Mar 2026 stood at $38.2 million (up 13.29% YoY), while the FY2025 annual figure was $36.8 million, down 18.75% from the prior year.
- Assets Average advanced to $38.2 million in Q1 2026 per TOVX's latest filing, from $34.5 million in the prior quarter.
- Across five years, Assets Average topped out at $84.8 million in Q2 2022 and bottomed at $33.3 million in Q3 2025.
- Historically, Assets Average has averaged $54.5 million across 5 years, with a median of $52.0 million in 2024.
- Annual changes were most pronounced in 2022 — Assets Average jumped 82.21% — and 2024, when it slumped 35.37%.
- Theriva Biologics' Assets Average stood at $74.5 million in 2022, then slipped by 21.62% to $58.4 million in 2023, then plunged by 35.37% to $37.7 million in 2024, then declined by 8.46% to $34.5 million in 2025, then grew by 10.73% to $38.2 million in 2026.
- Business Quant data shows TOVX's Assets Average at $38.2 million in Q1 2026, $34.5 million in Q4 2025, and $33.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - | 36.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.55 Mn |
| Mar 31, 2026 | 38.24 Mn |
| Dec 31, 2025 | 34.54 Mn |
| Sep 30, 2025 | 33.33 Mn |
| Jun 30, 2025 | 34.00 Mn |
| Mar 31, 2025 | 33.76 Mn |
| Dec 31, 2024 | 37.73 Mn |
| Sep 30, 2024 | 41.25 Mn |
| Jun 30, 2024 | 45.56 Mn |
| Mar 31, 2024 | 51.97 Mn |
| Dec 31, 2023 | 58.38 Mn |
| Sep 30, 2023 | 63.50 Mn |
| Jun 30, 2023 | 66.67 Mn |
| Mar 31, 2023 | 69.87 Mn |
| Dec 31, 2022 | 74.49 Mn |
| Sep 30, 2022 | 78.88 Mn |
| Jun 30, 2022 | 84.82 Mn |
| Mar 31, 2022 | 79.68 Mn |
| Dec 31, 2021 | 72.74 Mn |
| Sep 30, 2021 | 76.19 Mn |